HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.

Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may potentially improve outcomes for patients with ovarian cancer. HER...

Descrición completa

Detalles Bibliográficos

Principais autores:	Marianne Tuefferd, Jérôme Couturier, Françoise Penault-Llorca, Anne Vincent-Salomon, Philippe Broët, Jean-Paul Guastalla, Djelila Allouache, Martin Combe, Béatrice Weber, Eric Pujade-Lauraine, Sophie Camilleri-Broët
Formato:	Artigo
Idioma:	Inglês
Publicado:	Public Library of Science (PLoS) 2007-11-01
Series:	PLoS ONE
Acceso en liña:	http://europepmc.org/articles/PMC2042515?pdf=render
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!